Lanham Act covers ads that drug is FDA-approved/has ANDA

Arbor Pharmaceuticals, LLC v. ANI Pharmaceuticals,
Inc., 2018 WL 3677923, No. 17-4910 (D. Minn. Aug. 2, 2018)
Arbor sells prescription erythromycin ethylsuccinate
for oral suspension, allegedly the only FDA-approved products of their kind on
the market. ANI announced the launch of its own erythromycin ethylsuccinate for
oral suspension, allegedly claiming to be a generic version of Arbor’s products
and falsely claiming FDA approval/AB-rating pursuant to an approved Abbreviated
New Drug Application (ANDA). A product similar to an NDA-approved drug may be
approved and marketed based on an ANDA, which requires a showing of therapeutic
equivalence; the resulting AB-rating communicates that the product is a true
generic.
Arbor alleged that ANI acquired an ANDA from another
pharmaceutical company for a discontinued product that had been manufactured
using a process that differs from that used by ANI, and that the FDA has
notified ANI that its application wasn’t approvable. ANI stated that the
relevant ANDA was originally approved in 1978 for Barr Pharmaceuticals, that
Barr stopped marketing the approved product in 2003, and that the ANDA was
discontinued. ANI said that it filed a supplement to the ANDA with the FDA,
detailing changes it made to the manufacturing process, and indicated its
intent to market the product if the FDA did not advise otherwise within 30
days. The FDA allegedly didn’t object, so it must know and be ok with it.  [Nice work if you can get it.]
ANI argued that Arbor’s claims were precluded under
the FDCA. Despite Pom, courts have
continued to find preclusion where a plaintiff’s claims would require a court
to interpret and apply the FDCA.  This
wasn’t such a case.  Arbor asserted
competitive injury and sought to enforce the Lanham Act’s prohibition on false
advertising, here false representations of FDA approval.  ANI stated that it owned an ANDA that couldn’t
be circumvented by Arbor’s pleadings, and that the FDA tacitly approved of ANI’s
actions, but those were just statements in a brief, whereas Arbor alleged that
the FDA considered the ANDA discontinued and had so notified ANI.  Also, the FDA has a list of approved
generics, and ANI’s product isn’t on the latest printing.  Because the allegations were that ANI falsely
promoted its product as a generic equivalent, no interpretation of the FDCA was
required.

For the same reason, the primary jurisdiction doctrine didn’t justify declining
to decide the case.  Likewise, state and
common-law claims weren’t preempted, though the unfair competition claim under
Minnesota law was dismissed as merely duplicative of the false advertising
claim.

from Blogger https://ift.tt/2vs5Gtb

Posted in Uncategorized | Tagged , | Leave a comment

Keyword ad buys are fine for less expensive products too, court confirms

Lasoff v. Amazon.com, Inc., 2018 WL 3720029, —
Fed.Appx. —-, 2018 WL 3720029, No. 17-35173 (9th Cir. Aug. 6, 2018)
Lasoff sued Amazon and appealed the grant of summary
judgment on his trademark infringement and false advertising claims.  He argued that Amazon infringed Lasoff’s
trademark Ingrass by buying it for keyword ads. 
“Amazon is permitted to use a trademarked search term to direct
consumers to competing products, as long as the search results are clearly
labeled.” There was no evidence of lack of clear labeling.  Lasoff argued that MTM was distinguishable because consumers are more discerning as to
watches than as to artificial turf, the product here. The court disagreed,
making clear that noises about sophistication with respect to the underlying
product have always been makeweight; the real issue is sophistication about
search.  “The question is whether
consumers are confused by the search results, and those results display the
trademarked product names. The display of names in a set of search results is
not made more or less confusing simply because the underlying products might be
watches or turf.”

from Blogger https://ift.tt/2APlmf3

Posted in Uncategorized | Tagged , | Leave a comment

Allegations of “copycatting” in high tech industry plausibly accuse target of patent infringement

Global Tubing LLC v. Tenaris Coiled Tubes LLC, No.
4:17-CV-3299, 2018 WL 3496739 (S.D. Tex. Jul. 20, 2018)
The parties compete in the market for coiled tubing products
for the oil and gas industry. They and one other company allegedly dominate the
“highly competitive” coiled tubing marketplace in the U.S. (Id.) Global Tubing
characterizes that market as “a small, close-knit community,” in which
“[e]verybody knows everybody.” Tenaris launched BlueCoil and Global Tubing
subsequently launched Duracoil, both using a similar manufacturing process.
Global Tubing alleged false advertising based on several
statements: (1) at “the primary industry trade show in Houston,” a Global
Tubing employee asked Tenaris’s Chief Technology Officer whether he had seen
Global Tubing’s product launch. He said he had, but could not speak with the
Global Tubing employee because, in his words, ‘I can tell you right now we’re
probably going to court.’ ” (2) At the trade show, attended by nearly all the
customer base, Tenaris allegedly represented to existing and prospective Global
Tubing customers that Duracoil was a “copycat” of BlueCoil. (3) A Tenaris
employee allegedly told a Tenaris customer that Global Tubing “stole” the Duracoil
name from Tenaris, which considered Duracoil as a possible name for the product
that it eventually chose to name BlueCoil. (4) Tenaris’s CTO allegedly told a
“coiled tubing sales representative”−not identified by name or employer that
Tenaris had a patent that covered Duracoil, which was allegedly false because
the relevant patent had not yet been issued. The rep allegedly responded by
asking whether Tenaris would be owed royalties. Global Tubing also alleged that
Tenaris accused Global Tubing of copying in filings to the PTO in responding to
non-obvoiusness issues raised by the examiner.
The court declined to dismiss the false advertising
claim.  Tenaris argued that the
statements weren’t made in “commercial advertising or promotion.”  The key was whether Tenaris’s alleged
statements were disseminated sufficiently to the relevant purchasing public,
and the Fifth Circuit has said that “[w]here the potential purchasers in the
market are relatively limited in number, even a single promotional presentation
to an individual purchaser may be enough to trigger the protections of the
Act.” Given the allegations, the complaint passed, though more specificity would
be needed for summary judgment.  (The
statements to the PTO weren’t “commercial advertising or promotion,” though.)
Tenaris argued that “copycat” was just puffery, which is
exaggerated or vague. For 12(b)(6) purposes, the court disagreed:
Made in relation to a
high-technology product used by a high-dollar industry, the suggestion of ‘copying’
could quite reasonably be interpreted as an insinuation of patent infringement.
That a third-party customer sales representative thought Global Tubing might
owe royalties to Tenaris indicates as much…. [T]he claim made here−that one
company copied another’s technology−is one resolved frequently through patent
litigation. It is therefore more appropriate to view the statement as one
admitting of falsification and verification, rather than as one amounting only
to bluster or opinion.
Tenaris argued that Global Tubing didn’t adequately plead
injury or causation, given that it alleged that has received “very positive”
feedback from customers.  Nonetheless, “[t]hough
general, Global Tubing’s allegations sufficiently assert a plausible
reputational injury from Tenaris’s statements.”

from Blogger https://ift.tt/2v3J8Ow

Posted in Uncategorized | Tagged | Leave a comment

Plastic not so fantastic: video shot in medical facility didn’t defame or infringe facility’s TM rights

Weirton Medical Center, Inc. v. Introublezone, Inc., 2018 WL
3458261, J-A06003-18 (Pa. Super. Ct. Jul. 18, 2018)
Dr. Craig Richard Oser was a plastic surgeon with staff
privileges at plaintiff WMC from 2009 to 2014, making him an employee according
to WMC.  Dr. Oser entered into an
agreement with defendants to create a reality show, “Drastic Plastic,” “intended
to highlight the most salacious elements of Dr. Oser’s practice at WMC. Among
other things, the production dubbed Dr. Oser ‘The Vagician’ because of his
specialization in labiaplasty and vaginal reconstruction.”  A “sizzle reel” was filmed at WMC’s Medical
Office Building, and included statements by individuals who identified
themselves as Dr. Oser’s patients and employees. The video labeled the patients
“crazy” and included offensive references to Dr. Oser’s work in breast
augmentation, allegedly portraying the residents of West Virginia as uneducated
and willing to waste money on unnecessary plastic surgery. The video allegedly
appeared to include images of actual patient medical files. WMC alleged that it
did not consent or authorize the use of its facilities for this purpose. The
video was posted on Vimeo, as well as on Dr. Oser’s website and Facebook page.
WMC sued for defamation, violation of the Lanham Act, and
trespass.  The trial court watched the
Video “three times” and found “nothing defamatory. Poor taste, yes;
Defamation—No.” Nothing in nthe video identified WMC; plaques and pictures on
the wall were illegible.  “That Dr. Oser
is an employee of [WMC] is well known and [WMC] has advertised his employment
by it. Nevertheless, this connection does not give rise to a cause of action
for something he did, with others, that [WMC] doesn’t like but does not defame
it.” The trial court dismissed all the claims.
WMC appealed, arguing that the trial court shouldn’t have
watched the video when it wasn’t attached to the complaint. Under federal law,
this is easy: the video is a document essential to understanding the claims.  The court of appeals here agreed (over a
dissent): you can’t tell whether the video is capable of defamatory meaning without
viewing the video.  Anyway, there was no
prima facie case for defamation. Nothing in the video identified WMC.  WMC argued that the use of “WMC’s identifying
characteristics, medical professionals and employees (most notably Dr. Oser),
and facilities in the Video creates the reasonable likelihood that individuals
will believe that WMC is associated with or otherwise endorses Drastic
Plastic.” But WMC didn’t allege where in the video these uses were made, and
the other material surrounding the proposed show had no mention of WMC.  Even if WMC had been identified in the video,
WMC didn’t allege the defamatory character of the video as to WMC—defamation requires more than annoyance or embarrassment.
False association and/or false advertising under the Lanham
Act: WMC didn’t allege a relevant trademark, only use of “names and likenesses
of [WMC’s] medical professionals and employees (in particular, Dr. Oser),
facilities, and confidential patient information.” There were no allegedly
false statements about WMC’s medical services.
However, WMC did state a claim for trespass.  Dr. Oser’s apparent authority to authorize
defendants to enter was a factual issue not suited for dismissal.  [Hmm… Too bad there’s no anti-SLAPP law
here.] “WMC’s damages may be limited to two peppercorns, but it has pled a
sufficient claim to get past the preliminary objection stage.”

from Blogger https://ift.tt/2LAsNb1

Posted in Uncategorized | Tagged , | Leave a comment

non-lawyer’s purchase of “trademark attorney” as a keyword doesn’t itself plausibly deceive consumers

LegalForce RAPC Worldwide P.C. v. Swyers, No.
17-cv-07318-MMC, 2018 WL 3439371 (N.D. Cal. Jul. 17, 2018)
LegalForce alleged that defendants operated “TTC Business
Solutions,” providing “trademark related services,” and that they “engag[ed] in
the unlawful practice of law” as well as in false advertising.  LegalForce further alleged that the USPTO
prevented LegalForce from competing with defendants by enforcing its
“regulations” and “rules” against LegalForce RAPC but not against defendants.
The false advertising claims had to satisfy Rule 9(b)
because they used the words “false” and “misleading” [pause to note my
disagreement with this idea, especially when trademark infringement claims don’t
have to do so, but this is certainly a common result], and they didn’t because
there wasn’t sufficient detail about where the statements were made (what part
of the defendants’ website), etc. This disposed of claims based on the allegedly false “Created by Former USPTO Attorneys,” “Trusted by Over 100,000 Businesses Since 2003,”  and  “As featured in Time, Yahoo! Finance, and CNNMoney.com.”
Additionally, the claim “#1 in Trademark Registrations,” absent
further context, was puffery: a “general assertion[ ] of superiority” that
lacks “the kind of detailed or specific factual assertions that are necessary
to state a false advertising cause of action.” 
Claims based on defendants’ purchase of keywords related to
the practice of trademark filing, including “trademark attorney” and “trademark
lawyers,” were also dismissed. 
Plaintiffs alleged that purchasing keywords including defendant’s
website name “Trademarkia” led consumers to believe that they’d receive the
same attorney-led trademark filing services from both parties. Again, the
claims failed to satisfy 9(b) by, among other things, failing to identify the
ad copy that allegedly misled consumers or falsely compared the parties.  Furthermore, plaintiffs’ theory that consumers
who ended up on defendants’ website after searches for “trademark attorney,”
“trademark lawyers,” or “Trademarkia” were likely to be deceived would require
a a showing that the website was “likely to mislead consumers” into believing the
website was affiliated with an attorney. But the complaint failed to allege
sufficient facts to support such a finding, particularly given plaintiffs’
acknowledgement that the website states that the website operator “is not a law
firm and,” that “its trademark filing service is not a legal service,” and that
it “may not perform services performed by an attorney.”
The same fate awaited allegations that the “design” of the
website has “substantially the same logo, look, feel, and trade dress” as a
related entity’s website, which entity was
a law firm, allegedly misleading consumers into “the false impression that the
two websites are run by the same or similar entities or lawyers.”
Claims against the USPTO for deprivation of due process also
failed.  Plaintiffs alleged that the
USPTO has deprived LegalForce RAPC of its “right to engage in [its] chosen
occupation,” which is “practicing trademark law,” by promulgating a number of
regulations, and requiring LegalForce RAPC, but not defendants, to comply with
them. Such a claim requires a plaintiff to show “first, that [it is] unable to
pursue an occupation in the [chosen field], and second, that this inability is
due to actions that were clearly arbitrary and unreasonable.” But LegalForce
RAPC didn’t allege that it was unable to pursue the practice of trademark law;
instead, plaintiffs alleged that it “has been the largest law firm filer of
trademarks before the USPTO for the past five years.” So too with equal
protection claims, which when based on an unequal enforcement theory require
that “the selection was deliberately based upon an unjustifiable standard such
as race, religion, or other arbitrary classification.” There were no such
allegations.

from Blogger https://ift.tt/2O43zDt

Posted in Uncategorized | Tagged | Leave a comment

Six-year prison sentence for false advertising online

United States v. Arif, No. 17-1597, 2018 WL 3454467 (1st
Cir. Jul. 18, 2018)
A reminder that false advertising can be subject to criminal
penalties: Mustafa Hassan Arif sold non-prescription drug products that
purported to treat or cure hundreds of different diseases and medical
conditions from over 1,500 websites containing altered clinical studies,
fabricated testimonials, and false indicia of origin (designed to make
customers think they were buying from within their own Western countries,
rather than from Pakistan) and made more than $11 million in revenues. He
conditionally pled guilty to wire fraud in 2016 and was sentenced to
seventy-two months of imprisonment.  The
court of appeals affirmed the sentence.
Arif argued that he could only be prosecuted under the FTCA,
not the wire fraud statute. But the wire fraud statute, even assuming that it
was enacted before the FTCA (it was not, but it was based on the pre-FTCA mail
fraud statute), wasn’t impliedly repealed by the FTCA to the extent of any
overlap. The statutes addressed different activities—wire fraud, requiring the
use of “wires,” versus only false advertising, but in any medium. Overlap isn’t
enough to require the use of one statute instead of another where both are
clear, as here. United States v. Batchelder, 442 U.S. 114 (1979), held that
“when an act violates more than one criminal statute, the Government may
prosecute under either so long as it does not discriminate against any class of
defendants”:
This case provides a good example
for why Congress has vested discretion in the prosecutorial agencies as to
which statute to employ. The offense here was not a run-of-the-mill false advertising
of a single product. Arif, in order to make millions, mounted an elaborate
worldwide scheme to defraud: he deliberately posted numerous false and
misleading statements on over a thousand websites that he created and
maintained in order to gull those with medical ailments into purchasing his
products. The FTCA penalties for first or second offenders would hardly have
been an adequate deterrent for such egregious conduct. Crime must be made not
to pay.
Arif also argued that the court should have allowed his
defense that he did not commit wire fraud because he was pure of heart and mind
as to the efficacy of his products. But Arif was not being charged “with selling
drugs that did not work as intended … or for harming his customers.” Rather,
he was charged with “making misrepresentations on his websites,” which were
designed to give false comfort to buyers, in order to induce their purchases. Arif
knowingly misrepresented, among other things, that: (1) there was clinical
research showing outstanding results for the drugs he sold, including specific
cure rates; (2) actual customers attested to the efficacy of the drugs; and (3)
his businesses were operating from various western countries.  That was more than enough for intent.  False statements in service of a subjective
greater “truth” aren’t allowed.  [Ah, for
such a rule in politics.]  The falsities
here were material—indeed, they “went to the heart of his customer’s purchases.” 
Nor did the disclaimer on the third-party credit-card
processor’s website suffice: “[T]he product(s) purchased are not intended to
diagnose, mitigate, treat, cure or prevent any disease or health condition, and
I will not use any information or statements contained on the website through
which this product is purchased, or contained on or in such product(s), for
such purposes.  Arif argued that any
potential customer of “reasonable prudence” should have known not to rely on
the other statements on his website after reading this statement.  But reliance is not an element of wire fraud,
so that didn’t matter.

from Blogger https://ift.tt/2NwQ5zk

Posted in Uncategorized | Tagged | Leave a comment

New on Jotwell: reviewing Virginia Eubanks, Automating Inequality

Rebecca Tushnet, The Difference Engine: Perpetuating Poverty Through Algorithms, JOTWELL (July 18, 2018) (reviewing Virginia Eubanks, Automating Inequality: How High-Tech Tools Profile, Police, and Punish the Poor (2018))

from Blogger https://ift.tt/2LfQBnN

Posted in Uncategorized | Tagged , | Leave a comment

ASTM v. PublicResource.org: Trademark

American Society for Testing and Materials v.
Public.Resource.Org, Inc., No. 17-7035 (D.C. Cir. Jul. 17, 2018)
Trademark: This was where the district court went very, very
wrong—I consider the copyright issues difficult though I have a preferred
outcome; the trademark issues should not have been.
ASTM has registrations for ASTM word marks and stylized ASTM
logos, which they place on the cover pages of their technical standards. The
first page of a standard introduces the name of the work by depicting the “ASTM
International” logo and placing it next to the text.  Each subsequent page of the work includes a
header that again displays the ASTM logo and places it next to text indicating
a short title.

PRO copied these, which ASTM alleged constituted trademark infringement.  The district court found that PRO’s
disclaimers didn’t work because they “do not mention [PRO’s] creation of the
reproductions, [the SDOs’] lack of association or authorization, or that they
are even reproductions or transcriptions.”  Thus, consumers would be confused about
whether these were authentic copies of ASTM’s works, even though PRO “did not
undertake the same quality control procedures,” which, in turn, would harm
ASTM’s brand identity and goodwill.
Although Dastar was
itself about the creation of an unauthorized derivative work, the court of
appeals said that Dastar might well
preclude a claim based on reproduction of identical copies of the standards,
but that allegations of creation of unfaithful copies “through scanning and
re-typing, with resultant errors and differences,” didn’t fall within Dastar. 
The reason was that consumers who downloaded copies from PRO’s website
might attribute the digital files, and their errors, to ASTM, risking confusion
about “the tangible product sold in the marketplace.” Thus, the court of
appeals reasoned, “post-Dastar cases
where courts have found trademark claims foreclosed involved instances of
virtually identical copies,” which is descriptively untrue as well as failing
to account for the facts of Dastar.  [The court’s flawed distinction does highlight
the difficulty Dastar poses when the copying is of material that (allegedly) has secondary meaning—it’s notable that what’s missing in the identical copy situation,
in the court’s reasoning, is not the confusion,
which could well be unabated; it’s just the harm
to ASTM’s goodwill from the confusion. 
And in an alternate scenario where the defendant was selling copies, there could well be substitutionary harm, as
there could well have been in Dastar itself,
since some consumers will not be like my son and will buy only one series about
WWII campaigns in Europe.  If we let
plaintiffs plead around Dastar by
alleging confusion over the source of the copies, then Dastar becomes a dead letter.  The better solution would be to say that when the alleged confusion stems from the content itself, error-filled or otherwise, Dastar is triggered.]
The question then was the relevant likelihood of confusion
test, which is usually the multifactor test. However, nominative fair use accommodates
situations where it would be “virtually impossible to refer to a particular
product for purposes of comparison, criticism, point of reference or any other
such purpose without using the mark.” The district court declined to consider
nominative fair use because it had already found that consumer confusion was
likely; this was error.
There is a robust split about how to evaluate nominative
fair use—as a substitute for the usual confusion test, an affirmative defense,
or [ugh] as add-on factors—but the panel didn’t make a decision today for the
DC Circuit. “Where, as here, there is a claim of nominative fair use, the
likelihood of confusion analysis remains incomplete without at least some
discussion of these factors.”  Given that
PRO can reproduce some of the standards under copyright fair use, “it is hard
to see how PRO could fulfill that goal without identifying the standard by its
name—the very name also used in the incorporating law.”  And as for whether only so much was used as
reasonably necessary, “it may well be that PRO overstepped when it reproduced
both ASTM’s logo and its word marks but, as it told the district court, it is
not wedded to using the logo.”  So this
might point to a narrower remedy. 
And as to whether the user suggested sponsorship or
endorsement, PRO’s disclaimers “may well fail to adequately eliminate the possibility
a consumer would assume sponsorship or endorsement by ASTM, but that hardly
means that no disclaimer could cure that risk.” 
[Of course, case after case in the 9th Circuit (and some
elsewhere) has held that disclaimers aren’t required; the question under
nominative fair use is whether the defendant has done anything else affirmatively, other than use the mark, to suggest sponsorship.  I also have some words I could say about the
DC Circuit’s attitude towards disclaimers generally, but I shall resist.]  PRO had already modified the disclaimers to
disclose that it’s the one doing the scanning, that errors are its own, and
that it wasn’t affiliated with any organizations. “[E]ven if the district court
ultimately concludes that the record supports an infringement finding, it
should consider whether its previous grant of an injunction barring all
unauthorized use is still warranted or whether it ‘may order defendants to
modify their use of the mark so that all three factors are satisfied’ and a narrower
remedy would suffice.”

from Blogger https://ift.tt/2uJiZUU

Posted in Uncategorized | Tagged , | Leave a comment

ASTM v. PublicResource.org: Copyright

American Society for Testing and Materials v.
Public.Resource.Org, Inc., No. 17-7035 (D.C. Cir. Jul. 17, 2018)
The panel, citing “serious constitutional concerns,” vacated
the district court’s finding of trademark and copyright infringement based on
PRO’s copying of privately drafted standards that have been incorporated into
law in various jurisdictions.  Finding
errors in the district court’s dual fair use analyses, the court left for
another day “the far thornier question of whether standards retain their
copyright after they are incorporated by reference into law.”  The court also left it to the district court
to re-apply copyright fair use after further factfinding, and to determine how
to apply nominative fair use.
Incorporation into law varies across jurisdictions, as do
the legal consequences thereof, across thousands of technical standards (over
1200 ASTM standards in the CFR alone). 
Some incorporated standards define legal obligations, while others are “mere
references” that “have no direct legal effect on any private party’s conduct,”
and there are others in the middle, e.g. that trigger agency obligations or
establish eligibility for federal programs.  The court of appeals disagreed with the
district court’s blanket treatment of standards for fair use purposes, thus
allowing it to avoid the larger constitutional question for some or perhaps all
of the infringement claims.
Treating this case as one involving fair use rather than
copyrightability also “limits the economic consequences that might result from
the [plaintiff] SDOs losing copyright—which they repeatedly emphasize would
jeopardize the continued development of high-quality standards—by allowing
copying only where it serves a public end rather than permitting competitors to
merely sell duplicates at a lower cost.” 
And it avoids difficult questions about what happens, for example, when
a newer version of a standard becomes incorporated—would older versions regain
any lost copyright?  If necessary, these
issues might have to be reached on a fuller record.
Fair use: The district court found that the purpose of PRO’s
copying was “for the direct purpose of undermining [the SDOs’] ability to raise
revenue.” The record didn’t support that conclusion: “by all accounts, PRO
distributed these standards for the purpose of educating the public about the
specifics of governing law.” Further, the district court failed to consider
each standard on its own facts.  This
might not require individual factual development as to each standard, but
rather might allow for groupings that are fair use-relevant.
As for the commerciality of the use, the district court
found that PRO’s use had commercial elements because it distributed identical
standards in the same consumer market. 
This was too broad a definition of commerciality.  [Happy sigh.] 
Although PRO’s copies might serve as substitutes, “little, if anything,
in the record indicates that PRO stands to profit from its reproduction.” Even
if distributing the standards is part of PRO’s fundraising appeal, “that hardly
rises to the level of making this a ‘commercial’ use.” [Happier sigh.]
As a general matter, freely distributing standards
incorporated by reference into law furthers the purposes of fair use. Transformativeness
is important, and format change isn’t transformation for these purposes, but a
purpose to facilitate public access could be transformative without altering
the original work. (Citing A.V. ex rel. Vanderhye v. iParadigms, LLC, 562 F.3d
630 (4th Cir. 2009), and Swatch Group Management Services Ltd. v. Bloomberg
L.P., 756 F.3d 73 (2d Cir. 2014)).
Exact copying can be important to understand, say, one’s
legal obligations, and where this is so, “this factor would weigh heavily in
favor of permitting a nonprofit seeking to inform the public about the law to reproduce
in full the relevant portions of that particular standard.”  For example, federal law’s incorporation of
ASTM specifications to “dictate” whether a retailer of diesel fuel needs to
provide additional fuel labels likely favors PRO’s copying, while using ASTM
standards as a reference procedure for determining whether gasoline without ethanol
has an “[e]vaporated initial boiling point” of “75- 95[°F],” likely doesn’t.  Copying the version that is incorporated in
federal law is also likely to be favored over copying a later edition that is not so incorporated (though the court doesn’t
here discuss copying prior versions so
that the public can see what’s changed over time—something of particular interest
as this administration dumps ever more once-public information down the memory
hole).
“[W]here knowing the content of an incorporated standard
might help inform one’s understanding of the law but is not essential to
complying with any legal duty, the nature of PRO’s use might be less
transformative and its wholesale copying, in turn, less justified” because
paraphrase or summary might be adequate to serve the purpose.  [Would paraphrase avoid an infringement claim
based on structure, sequence, and organization? The court seems to assume the
answer is yes, and I think it should, but I’m not confident it would. 
Query also how much room there is to rephrase a reference procedure for
determining an initial boiling point; that sounds a little merger-y to me.]  Purpose has to be assessed use by use, even
though that may be difficult.
Factor two: “All of the works at issue here fall at the
factual end of the fact-fiction spectrum, which counsels in favor of finding
fair use.”  But the district court found
that because technical standards “are vital to the advancement of scientific
progress in the U.S.,” they are “exactly the type of expressive work that
warrants full protection under . . . the Copyright Act.” If these were “ordinary
technical standards used for no public purpose,” the court of appeals might
have agreed. [Though it shouldn’t have! Patent and copyright are different, and
“science” now means something very different than it did in “Science and Useful
Arts.”]  But these standards have all, in
some capacity, been incorporated by reference into law, and, “the express text of
the law falls plainly outside the realm of copyright protection.” Standards
incorporated by reference into law are thus, “at best, at the outer edge of ‘copyright’s
protective purposes,’” though just how far at the edge depends on the degree of
incorporation, as above.
Factor three: Must be considered standard by standard, in
light of PRO’s purpose.  “If PRO limits
its copying to only what is required to fairly describe the standard’s legal
import, this factor would weigh strongly in favor of finding fair use here,
especially given that precision is ten-tenths of the law.”  So where specific provisions are incorporated
into law, maybe you can only copy those provisions [and I presume any
provisions required to understand those provisions—the court of appeals doesn’t
mention cross-references, but given its discussion, definitional and other
foundational provisions would have to be fair game as well].  Where the law refers generally to a standard’s
specifications, by contrast, a greater amount of copying would be allowed. “And
where the incorporation merely makes reference to an external standard, but
that standard does not govern any conduct, perhaps the copier’s purpose could
be achieved with only a paraphrase or a summary.”
Factor four: first, the district court erred in presuming market
harm based on PRO’s [nonexistent] commercial purpose. The record didn’t show
how serious any adverse impact on the SDOs’ market might be.  On remand, the district court should consider
that (1) the SDOs already make copies of their standards freely available
online (in “controlled reading rooms”), presumably “without entirely
cannibalizing sales of their standards.” 
How much additional harm could PRO’s copying cause?  (2) The market harm question has to be
addressed with reference to the legal alternatives—that is, if PRO were only to
reproduce the portions of a longer standard that were actually incorporated
into law, “would there still be a vibrant market for the standards in their
entirety?” [There are a couple of ways to read this, but I think one significant
point is this: suppose that partial copying had the same effect on the market
as full copying.  Given that such partial
copying is fair use, then the marginal market impact of PRO’s infringing use would
be zero.  Of course, partial copying
might not have the same effect on the market.] 
(3) What’s up with derivative works? 
Because SDOs routinely update their standards, “in many cases, the
edition PRO posts to the internet—and, indeed, the one incorporated into the law—is
long outdated.” Does PRO’s copying of old standards harm the market for
updated, unincorporated editions?  If the
SDOs are to be believed, the primary purpose of technical standards is “to have
them used by private industry and other non- governmental users to address
technical issues or problems,” indicating that “market demand for the most
up-to-date standards would be resilient.” 
Does the SDOs’ ability to market derivatives provide an adequate
incentive to continue producing standards even with PRO’s copying?  Even after Veeck v. Southern Building Code
Congress International, Inc., 293 F.3d 791 (5th Cir. 2002), the successor SDO
remains profitable both through sales of codes and of “program services,
including consulting, certification, and training.”
Ultimately, genuine issues of material fact precluded
summary judgment on copyright fair use.
Judge Katsas concurred to emphasize that law cannot be
copyrighted and that the majority opinion was pretty clear that “[W]here a
particular standard is incorporated as a binding legal obligation, and where
the defendant has done nothing more than disseminate it, the Court leaves little
doubt that the dissemination amounts to fair use.” 

from Blogger https://ift.tt/2LjEfLq

Posted in Uncategorized | Tagged , | Leave a comment

Unclean (but collagen rich) hands in a false advertising case

Certified Nutraceuticals, Inc. v. Avicenna Nutraceutical,
LLC, 2018 WL 3361142, No. 16-cv-02810-BEN-BGS (C.D. Cal. Jul. 10, 2018)
A rare unclean hands victory in a false advertising case.  Certified alleged that Avicenna, its
competitor in the market for collagen products used as ingredients in other
products, falsely advertised its products as “patented” or processed using
“patented formulas and production methods” while Avicenna never held any
relevant patents.
To prevail on a defense of unclean hands, a defendant must
demonstrate by clear and convincing evidence: (1) “that the plaintiff’s conduct
is inequitable;” and (2) “that the conduct relates to the subject matter of
[the plaintiff’s] claims.” Even in such cases, unclean hands isn’t
automatically a defense; the plaintiff’s wrongdoing must be balanced against
the defendant’s, considering the substance of the plaintiff’s rights.
In the Ninth Circuit, “only a showing of wrongfulness,
willfulness, bad faith, or gross negligence, proved by clear and convincing
evidence, will establish sufficient culpability for invocation of the doctrine
of unclean hands.”  Here, Avicenna
established that Certified falsely claimed patent protection for its competing
product, over a year before the PTO granted any Certified patent.  Certified argued that its product was covered
by a different patent, but Certified wasn’t an owner, assignee, or licensee of that
patent at that time or since, perhaps because of a permanent injunction against
a Certified principal enjoining him from transferring, enforcing, or otherwise
affecting the title to that patent. 
Certified’s only other evidence that the statements weren’t false or
misleading was a false statement that the principal was the assignee of a
patent that was a continuation of the enjoined patent.  Thus, the court found that Certified
knowingly made statements about the patented nature of its product—either
because it knew the later patent hadn’t been issued, or because it knew it had
no right to manufacture, distribute, offer for sale, or sell any goods under
the continuation patent.  Avicenni showed
Certified’s wrongfulness, willfulness, and bad faith in engaging in inequitable
conduct with clear and convincing evidence. [I’m not sure courts would find
that claiming patent protection when the patent was pending always meets this
standard, though it would usually have to be knowing.]
Did this inequitable conduct relate to Avicenna’s false
advertising claim? Unclean hands should only be applied “where some
unconscionable act of one coming for relief has immediate and necessary
relation to the equity that he seeks in respect of the matter in litigation,” which
means that the plaintiff dirtied its hands “in acquiring the right” presently
asserted or “the manner of dirtying renders inequitable the assertion of such
rights against the defendants.” Even though the statements were now years old,
there was still an immediate and necessary relationship to the equitable
remedies sought, because they were about the patented status of the directly
competing products.
Summary judgment on Lanham Act claims granted; coordinate
state-law claims dismissed for want of supplemental jurisdiction.

from Blogger https://ift.tt/2NJHv13

Posted in Uncategorized | Tagged | Leave a comment